Brian A. Whiteman

Array ( [id] => 19120014 [patent_doc_number] => 11963975 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Therapeutic targets for facioscapulohumeral muscular dystrophy [patent_app_type] => utility [patent_app_number] => 17/489983 [patent_app_country] => US [patent_app_date] => 2021-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 37 [patent_no_of_words] => 20805 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17489983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786417 [patent_doc_number] => 20230374523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 18/027895 [patent_app_country] => US [patent_app_date] => 2021-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14612 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18027895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312821 [patent_doc_number] => 20210401869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => Antisense Compounds Targeting Genes Associated with Cystic Fibrosis [patent_app_type] => utility [patent_app_number] => 17/472887 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19324855 [patent_doc_number] => 12042508 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-23 [patent_title] => Antisense compounds targeting genes associated with cystic fibrosis [patent_app_type] => utility [patent_app_number] => 17/472046 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 20206 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776860 [patent_doc_number] => 20220243209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => MODULATORS OF COMPLEMENT FACTOR B [patent_app_type] => utility [patent_app_number] => 17/465035 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465035 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18739937 [patent_doc_number] => 20230348906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => DUX4 INHIBITORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/043520 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19043766 [patent_doc_number] => 11932852 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof [patent_app_type] => utility [patent_app_number] => 17/463923 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 24 [patent_no_of_words] => 48064 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17444143 [patent_doc_number] => 20220064648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => NOVEL X-APTAMERS FOR THE USE IN DETECTION OF SNAP25 [patent_app_type] => utility [patent_app_number] => 17/458169 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8587 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692980 [patent_doc_number] => 20230323348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => COMPOSITIONS AND METHOD FOR TREATING THALASSEMIA [patent_app_type] => utility [patent_app_number] => 18/042015 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19104715 [patent_doc_number] => 11957788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-16 [patent_title] => Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications [patent_app_type] => utility [patent_app_number] => 17/405068 [patent_app_country] => US [patent_app_date] => 2021-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 14741 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18643470 [patent_doc_number] => 11767530 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Splice inhibiting oligonucleotides [patent_app_type] => utility [patent_app_number] => 17/387064 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 27847 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418783 [patent_doc_number] => 20240294906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => ATXN2 IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING ATXN2-ASSOCIATED NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 18/007007 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 104037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546659 [patent_doc_number] => 20220118000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => ANTISENSE OLIGOMERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/379793 [patent_app_country] => US [patent_app_date] => 2021-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 282856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17379793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597570 [patent_doc_number] => 20230272366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => Mutant of Pyruvate Carboxylase Gene Promoter and Use Thereof [patent_app_type] => utility [patent_app_number] => 18/016804 [patent_app_country] => US [patent_app_date] => 2021-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 202 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18124676 [patent_doc_number] => 20230010288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/371182 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18469218 [patent_doc_number] => 20230203502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => RNA SCAFFOLDS [patent_app_type] => utility [patent_app_number] => 18/008234 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18008234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552468 [patent_doc_number] => 20230250478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => DIAGNOSIS AND TREATMENT OF CHRONIC DIABETIC COMPLICATIONS USING LONG NONCODING RNAS AS TARGETS [patent_app_type] => utility [patent_app_number] => 18/014322 [patent_app_country] => US [patent_app_date] => 2021-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39876 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18014322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414349 [patent_doc_number] => 20220049253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES [patent_app_type] => utility [patent_app_number] => 17/356946 [patent_app_country] => US [patent_app_date] => 2021-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31963 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17356946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441749 [patent_doc_number] => 20220062254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES [patent_app_type] => utility [patent_app_number] => 17/354582 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17354582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17784888 [patent_doc_number] => 11408001 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-08-09 [patent_title] => Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/347863 [patent_app_country] => US [patent_app_date] => 2021-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 29 [patent_no_of_words] => 60193 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17347863 [rel_patent_id] =>[rel_patent_doc_number] =>)